Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.

Liu X, Ye Q, Zhao XP, Zhang PB, Li S, Li RQ, Zhao XL.

Clin Chim Acta. 2019 Feb;489:254-260. doi: 10.1016/j.cca.2018.08.040. Epub 2018 Sep 6. Review.

PMID:
30194935
2.

Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia.

Elghannam DM, Abousamra NK, Shahin DA, Goda EF, Azzam H, Azmy E, El-Din MS, El-Refaei MF.

Egypt J Immunol. 2009;16(1):9-15.

PMID:
20726318
3.

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD.

J Clin Oncol. 2008 Oct 1;26(28):4603-9. doi: 10.1200/JCO.2007.14.0418. Epub 2008 Jun 16.

4.

Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.

Al-Kzayer LF, Sakashita K, Al-Jadiry MF, Al-Hadad SA, Ghali HH, Uyen le TN, Liu T, Matsuda K, Abdulkadhim JM, Al-Shujairi TA, Matti ZI, Sughayer MA, Rihani R, Madanat FF, Inoshita T, Kamata M, Koike K.

Pediatr Blood Cancer. 2015 Dec;62(12):2157-61. doi: 10.1002/pbc.25683. Epub 2015 Jul 29.

PMID:
26222068
5.

DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.

Yuan XQ, Peng L, Zeng WJ, Jiang BY, Li GC, Chen XP.

Medicine (Baltimore). 2016 May;95(18):e3519. doi: 10.1097/MD.0000000000003519. Review.

6.

Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.

Liu WJ, Tan XH, Luo XP, Guo BP, Wei ZJ, Ke Q, He S, Cen H.

Leuk Lymphoma. 2014 Dec;55(12):2691-8. doi: 10.3109/10428194.2014.893308. Epub 2014 Mar 31. Review.

PMID:
24524305
7.

Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.

Tie R, Zhang T, Fu H, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H.

PLoS One. 2014 Jun 17;9(6):e93353. doi: 10.1371/journal.pone.0093353. eCollection 2014. Review.

8.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K.

Blood. 2013 Jan 3;121(1):170-7. doi: 10.1182/blood-2012-05-431486. Epub 2012 Oct 31.

9.

KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.

Zhou JD, Yao DM, Li XX, Zhang TJ, Zhang W, Ma JC, Guo H, Deng ZQ, Lin J, Qian J.

Oncotarget. 2017 Aug 2;8(39):66087-66097. doi: 10.18632/oncotarget.19798. eCollection 2017 Sep 12.

10.

ras oncogene activation and occupational exposures in acute myeloid leukemia.

Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E.

J Natl Cancer Inst. 1992 Nov 4;84(21):1626-32.

PMID:
1433344
11.

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G.

Leuk Res. 2015 Dec;39(12):1367-74. doi: 10.1016/j.leukres.2015.10.005. Epub 2015 Oct 19.

12.

Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.

Li HY, Deng DH, Huang Y, Ye FH, Huang LL, Xiao Q, Zhang B, Ye BB, Lai YR, Mo ZN, Liu ZF.

Eur J Haematol. 2015 May;94(5):439-48. doi: 10.1111/ejh.12450. Epub 2015 Jan 22.

PMID:
25227715
13.

Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.

Mao C, Fu XH, Yuan JQ, Yang ZY, Huang YF, Ye QL, Wu XY, Hu XF, Zhai ZM, Tang JL.

Cochrane Database Syst Rev. 2015 Nov 6;(11):CD010248. doi: 10.1002/14651858.CD010248.pub2. Review.

PMID:
26544114
14.

RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Sano H, Shimada A, Taki T, Murata C, Park MJ, Sotomatsu M, Tabuchi K, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y.

Int J Hematol. 2012 May;95(5):509-15. doi: 10.1007/s12185-012-1033-x. Epub 2012 Mar 10.

PMID:
22407852
15.

Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Xu Q, Li Y, Lv N, Jing Y, Xu Y, Li Y, Li W, Yao Z, Chen X, Huang S, Wang L, Li Y, Yu L.

Clin Cancer Res. 2017 Aug 1;23(15):4511-4522. doi: 10.1158/1078-0432.CCR-16-2628. Epub 2017 Feb 28. Review.

16.

Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Chen W, Xie H, Wang H, Chen L, Sun Y, Chen Z, Li Q.

PLoS One. 2016 Jan 15;11(1):e0146614. doi: 10.1371/journal.pone.0146614. eCollection 2016. Review.

17.

Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.

Shih LY, Liang DC, Huang CF, Chang YT, Lai CL, Lin TH, Yang CP, Hung IJ, Liu HC, Jaing TH, Wang LY, Yeh TC.

Leukemia. 2008 Feb;22(2):303-7. Epub 2007 Oct 25.

PMID:
17960171
18.

Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis.

Yi-Ning Y, Xiao-rui W, Chu-xian Z, Chun W, You-wen Q.

Ann Hematol. 2015 Jun;94(6):929-38. doi: 10.1007/s00277-014-2295-6. Epub 2015 Jan 10.

PMID:
25572170
19.

Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ.

Proc Natl Acad Sci U S A. 1988 Mar;85(5):1629-33.

20.

Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents.

Barletta E, Gorini G, Vineis P, Miligi L, Davico L, Mugnai G, Ciolli S, Leoni F, Bertini M, Matullo G, Costantini AS.

Carcinogenesis. 2004 May;25(5):749-55. Epub 2003 Dec 19.

PMID:
14688017

Supplemental Content

Support Center